When Evidence Falls Short-Belzutifan for Treating Tumours Associated with von Hippel-Lindau Disease: An External Assessment Group Perspective on a NICE Single Technology Appraisal.

IF 4.4 3区医学 Q1 ECONOMICS

PharmacoEconomics Pub Date : 2025-05-07 DOI:10.1007/s40273-025-01505-z

Isaac Corro Ramos, Susan O'Meara, Mubarak Patel, Lisa Stirk, Jiongyu Chen, Xiaoyu Tian, Nigel Armstrong

引用次数: 0

查看原文本刊更多论文

当证据不足时，贝祖替芬治疗与希佩尔-林道病相关的肿瘤：NICE单一技术评估的外部评估小组视角

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PharmacoEconomics 医学-药学

CiteScore

8.10

自引率

9.10%

发文量

审稿时长

6-12 weeks

期刊介绍： PharmacoEconomics is the benchmark journal for peer-reviewed, authoritative and practical articles on the application of pharmacoeconomics and quality-of-life assessment to optimum drug therapy and health outcomes. An invaluable source of applied pharmacoeconomic original research and educational material for the healthcare decision maker. PharmacoEconomics is dedicated to the clear communication of complex pharmacoeconomic issues related to patient care and drug utilization. PharmacoEconomics offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article.